1. Home
  2. GAB vs NVCR Comparison

GAB vs NVCR Comparison

Compare GAB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Equity Trust Inc. (The)

GAB

Gabelli Equity Trust Inc. (The)

N/A

Current Price

$5.42

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo NovoCure Limited

NVCR

NovoCure Limited

N/A

Current Price

$11.96

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GAB
NVCR
Founded
1986
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
GAB
NVCR
Price
$5.42
$11.96
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $25.57
AVG Volume (30 Days)
919.7K
★ 1.7M
Earning Date
01-01-0001
10-29-2026
Dividend Yield
★ 10.91%
N/A
EPS Growth
N/A
★ 21.79
EPS
★ N/A
N/A
Revenue
N/A
★ $655,353,000.00
Revenue This Year
N/A
$12.95
Revenue Next Year
N/A
$9.33
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 8.28
52 Week Low
$5.09
$9.82
52 Week High
$6.37
$21.45

Technical Indicators

Market Signals
Indicator
GAB
NVCR
Relative Strength Index (RSI) 60.04 32.38
Support Level $5.28 $11.73
Resistance Level $5.72 $18.43
Average True Range (ATR) 0.08 0.86
MACD 0.03 -0.17
Stochastic Oscillator 95.65 8.80

Price Performance

Historical Comparison
GAB
NVCR

About GAB Gabelli Equity Trust Inc. (The)

Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: